enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Interest Expense

Cost of servicing the company's debt during the period.

enGene Holdings Inc.NASDAQ: ENGN

Interest Expense · Q2 FY2026 · quarter ended Apr 2026

Interest expense grows in line with its trailing trend

Q2 FY2026 interest expense of $745K rose 1.5% year over year, ahead of the -0.3% change in trailing-twelve-month interest expense. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at +28.1% a year.

Context

  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1.5% holds above the trailing-twelve-month pace of -0.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$745K+1.8% QoQ
Last fiscal yearOct 2025
$2.99M+7.0% YoY
LTMApr 2026
$2.99M-0.3% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year+7.0%——
3-year CAGR+28.1%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
2.99M USD
Year-over-year change
+7.0%
4-year CAGR
-12.1%

Interest Expense vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.3% is the 6th highest of 7, against a peer median of +30.1%.
  • Over three fiscal years its annual growth of +28.1% compares with a peer median of +5.1%.
ENGN Competitors
Interest Expense for ENGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$8.49M USD+11.7%+28.9%12.5%
ENGNenGene Holdings Inc.LTM Apr 2026$2.99M USD-0.3%+28.1%—
ALTAltimmune, Inc.LTM Mar 2026$2.7M USD+29933.3%+489.2%7508.3%
ANROAlto Neuroscience, Inc.LTM Mar 2026$2.42M USD+48.5%——
DBVTDBV Technologies S.A.LTM Mar 2026$656.17K USD+480.7%——
ACIUAC Immune S.A.LTM Mar 2026CHF 156.68K CHF+3.8%-18.7%4.2%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD——0.0%
ANNXAnnexon, Inc.LTM Mar 2026$0 USD———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
AMRNAmarin Corporation plcLTM Mar 2026$0 USD-100.0%-22.4%0.0%
KRROKorro Bio, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ENGN) —+30.1%+5.1%2.1%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development12.46M15.47M16.46M38.32M94.48M
Selling, General & Admin3.16M3.26M8.47M23.98M28.69M
Operating Expenses15.87M19.43M26.06M62.3M123.17M
Depreciation & Amortization272K238K175K323K509K
EBITDA(18.15M)(22.78M)(94.77M)(52.04M)(113.8M)
EBITDA Margin—————
Operating Income(15.87M)(19.43M)(26.06M)(62.3M)(123.17M)
Operating Margin—————
Interest Income25K129K1.12M10.41M9.43M
Interest Expense5.02M1.42M4.95M2.8M2.99M
Other Income / Expenses(7.57M)(5.01M)(73.84M)7.14M5.86M
Income Before Tax(23.44M)(24.44M)(99.9M)(55.16M)(117.3M)
Pre-Tax Margin—————
Income Tax Expense022K17K(19K)0
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Net Margin—————
EPS (Basic)(0.01)0.00(4.24)(1.46)(2.29)
EPS (Diluted)(0.01)0.00(4.24)(1.46)(2.29)
Weighted Avg Shares15.81M15.81M23.56M44.64M51.12M
Weighted Avg Shares (Diluted)15.81M15.81M23.56M44.64M51.12M

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.